Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed CFO
Quarterly results
Director departure
Appointed director
CC transcript

IMCLONE SYSTEMS INC (IMCL) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/09/2008 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/26/2008 8-K Quarterly results
11/24/2008 SC 13D/A Carl Icahn reports a 0% stake in ImClone Systems Incorporated
11/21/2008 SC 13D/A LILLY ELI & CO has filed a Schedule 13D for IMCLONE SYSTEMS INCORPORATED
11/10/2008 10-Q Quarterly Report for the period ended September 30, 2008
11/05/2008 SC 13G/A Clearbridge Advisors, LLC reports a 0% stake in ImClone Systems Inc Address of issuers principal executive offices: 180 Varick Street 6th Floor New York, NY 10014 United States Item 2a) Name of person filing: ClearBridge Advisors, LLC Item 2b) Address of principal business office: 620 8th Avenue New York, NY 10018 Item 2c) Citizenship: ClearBridge Advisors, LLC Delaware Limited Liability Corporation Item 2d)
11/04/2008 8-K Form 8-K -- Current report
10/16/2008 SC 13D LILLY ELI & CO has filed a Schedule 13D for IMCLONE SYSTEMS INCORPORATED
10/08/2008 SC 13D/A Carl Icahn has filed a Schedule 13D for ImClone Systems Incorporated
10/08/2008 SC 13D/A BRISTOL MYERS SQUIBB CO reports a 16.6% stake in ImClone Systems Incorporated
10/08/2008 8-K Form 8-K -- Current report
10/07/2008 SC 13D/A Carl Icahn reports a 13.4% stake in ImClone Systems Incorporated
10/02/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS ISSUES STATEMENT"
09/29/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS ISSUES STATEMENT"
09/26/2008 8-K Other Events
09/25/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
09/23/2008 SC 13D/A BRISTOL MYERS SQUIBB CO reports a 16.6% stake in ImClone Systems Incorporated
09/16/2008 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
09/12/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS SUBMITS LETTER TO BRISTOL-MYERS SQUIBB"
09/12/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS ISSUES STATEMENT"
09/04/2008 8-K Other Events
09/02/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "ERBITUX ® PHASE 3 BMS-099 LUNG CANCER STUDY SECONDARY ENDPOINT UPDATE: OVERALL SURVIVAL RESULTS ANNOUNCED"
08/11/2008 8-K Other Events
08/08/2008 10-Q Quarterly Report for the period ended June 30, 2008
08/07/2008 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/06/2008 8-K Other Events
08/04/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS ISSUES STATEMENT"
08/01/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IMCLONE SYSTEMS ISSUES STATEMENT",
"Letter from BMS"
07/31/2008 SC 13D/A BRISTOL MYERS SQUIBB CO reports a 16.6% stake in ImClone Systems Incorporated
07/24/2008 8-K Quarterly results
Docs: "IMCLONE SYSTEMS REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS"
07/16/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "ERBITUX® RECEIVES APPROVAL IN JAPAN FOR USE IN ADVANCED COLORECTAL CANCER"
07/14/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "IMCLONE ANNOUNCES CHANGES IN COMMERCIAL ORGANIZATION LEADERSHIP"
06/30/2008 8-K Other Events
06/02/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "ERBITUX® DATA DEMONSTRATE IMPROVED OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER",
"RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improved Outcome for Lung Cancer Patients",
"NEW ANALYSES OF PIVOTAL PHASE 3 STUDY OF ERBITUX® DEMONSTRATE ENHANCED EFFICACY IN FIRST-LINE METASTATIC COLORECTAL CANCER PATIENTS WITH WILD-TYPE K-RAS BIOMARKER"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy